**GREEN MEMORY Trial**

The GREEN MEMORY trial is a 52-week, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial sponsored by Shanghai Green Valley Pharmaceutical Co. to evaluate the safety, tolerability, and efficacy of sodium oligomannate (GV-971) in treatment of mild to moderate Alzheimer's Disease. This investigational medication is designed to restore the natural balance of bacteria in the gut. There are certain bacteria that are thought to cause inflammation in the brain and nerves, possibly contributing to Alzheimer’s disease.

An estimated 2,046 participants across the US and Canada will be randomly assigned at a 1:1 ratio to receive either 450mg of GV-971 or placebo capsule taken orally twice daily. Subjects who successfully complete the double-blind treatment period may continue in a 26-week open-label extension (OLE), meaning they would be guaranteed to receive the active study drug at that point.

**Category:** Alzheimer’s Disease Research

**Study Population:** Individuals with Mild to Moderate Alzheimer’s disease

**Study Length:** 52 week treatment period with visits every 6 weeks, followed by 26 week open-label extension

**Requirements:**

* Adults 50-85 years old
* Must meet criteria for Mild to Moderate Alzheimer’s disease, confirmed during screening process for the trial (prior diagnosis not required)
* Individuals currently taking memory medications (Aricept, Exelon, Namenda, etc.) will be required to stop use while enrolled in the study.
* A study partner (family member, close friend, caregiver) who has known the participant for at least 1 year, assists the participant regularly at least 3 times per week, has knowledge of his/ her cognitive and functional states, and can accompany him/her to all study visits is required.
* Must sign an informed consent document indicating that he or she understands the purpose of the study, procedures required, and is willing to participate in the study. A legally authorized representative will be required to sign on the patient’s behalf if the subject is determined to not possess decision capacity.

**Benefits:**

There is no promise that you will receive any benefit from taking part in this study. Your participation in the study may help improve your Alzheimer’s Disease (AD) symptoms if you receive the study drug, but this is not guaranteed. Although you may not directly benefit from taking part in this study, the information and data from this study can be valuable in treating patients with AD in the future.

**Contact Information:**

Allison Acree, Lead Recruitment Coordinator – (843) 608-1950 xt.1109

Codi Cammer, Recruitment Coordinator – (843) 608-1950 xt.1110

Dr. Jacobo Mintzer, Principal Investigator – (843) 608-1950 xt.1101